Crossmark

Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?

Published Online: 2021-01-02

Published Print: 2021-01

Authors

Tabbò, Fabrizio

Passiglia, Francesco

Novello, Silvia https://orcid.org/0000-0001-7653-9748
License Information

Text and Data Mining valid from 2021-01-01

Version of Record valid from 2021-01-01
More Information

Article History

Accepted: 5 November 2020

First Online: 2 January 2021

Compliance with Ethical Standards

:

: Fabrizio Tabbo declares that he has no conflict of interest.Francesco Passiglia has received compensation from MSD and AstraZeneca for service as a consultant.Silvia Novello has received compensation from Eli Lilly, MSD, Roche, Bristol-Myers Squibb, Takeda, Pfizer, AbbVie, Celgene, AstraZeneca, and Boehringer Ingelheim for service as a consultant.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Document is current